MediSense preparing for launch of Precision QID third-generation blood glucose monitor.
• By The Tan Sheet
MEDISENSE PRECISION QID THIRD-GENERATION GLUCOSE MONITORING SYSTEM will begin U.S. shipments "at or around the end of this quarter," MediSense Chairman and CEO Robert Coleman, PhD, said at a May 16 session of the Alex. Brown & Sons health care seminar in Baltimore. Both the home glucose monitoring device and attendant disposable strips were cleared for marketing by FDA on March 23.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
Experts from EUCOPE explain why the Council of the EU’s position on the proposed overhaul of the general pharmaceutical legislation could offer more predictability for companies than the commission’s initial offering.